thyroxine has been researched along with Colorectal Neoplasms in 13 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with documented metastatic colorectal cancer and progression of disease during or within 3 months after the last standard therapy, with no evidence and history of previous thyroid disease were enrolled." | 5.46 | Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? ( Madeddu, C; Mariotti, S; Massa, E; Massidda, M; Pani, F; Pusceddu, V; Puzzoni, M; Scartozzi, M, 2017) |
| "In conclusion, T4 promoted colorectal cancer cell proliferation which could be repressed by tetrac and NDAT." | 5.43 | The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. ( Chin, YT; Davis, PJ; Incerpi, S; Lee, YS; Lin, HY; Liu, LF; Lu, YT; Pedersen, JZ; Shih, A; Wei, PL; Wu, HC; Yang, YSH, 2016) |
| " Therefore, we aimed to investigate the product of this enzyme, reverse triiodothyronine (rT3) in serum of newly diagnosed colorectal cancer (CRC) patients." | 4.02 | Colorectal cancer causes alteration of thyroid hormone profile in newly diagnosed patients. ( Ghorbani, A; Pourvali, K; Shimi, G; Zand, H, 2021) |
| "Patients with documented metastatic colorectal cancer and progression of disease during or within 3 months after the last standard therapy, with no evidence and history of previous thyroid disease were enrolled." | 1.46 | Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? ( Madeddu, C; Mariotti, S; Massa, E; Massidda, M; Pani, F; Pusceddu, V; Puzzoni, M; Scartozzi, M, 2017) |
| "Associations with cancer-related deaths were also explored." | 1.46 | Higher thyrotropin concentration is associated with increased incidence of colorectal cancer in older men. ( Alfonso, H; Chan, YX; Chubb, SA; Fegan, PG; Flicker, L; Golledge, J; Hankey, GJ; Yeap, BB, 2017) |
| "In conclusion, T4 promoted colorectal cancer cell proliferation which could be repressed by tetrac and NDAT." | 1.43 | The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. ( Chin, YT; Davis, PJ; Incerpi, S; Lee, YS; Lin, HY; Liu, LF; Lu, YT; Pedersen, JZ; Shih, A; Wei, PL; Wu, HC; Yang, YSH, 2016) |
| "Thyroid function in colorectal cancer patients receiving fluoropyrimidine-based chemotherapy with or without bevacizumab was evaluated at baseline and monthly." | 1.39 | Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TY | 1 |
| Chang, TC | 2 |
| Chin, YT | 5 |
| Pan, YS | 1 |
| Chang, WJ | 1 |
| Liu, FC | 1 |
| Hastuti, ED | 1 |
| Chiu, SJ | 1 |
| Wang, SH | 2 |
| Changou, CA | 2 |
| Li, ZL | 1 |
| Chen, YR | 4 |
| Chu, HR | 1 |
| Shih, YJ | 4 |
| Cheng, RH | 1 |
| Wu, A | 1 |
| Lin, HY | 5 |
| Wang, K | 2 |
| Whang-Peng, J | 3 |
| Mousa, SA | 1 |
| Davis, PJ | 5 |
| Shimi, G | 1 |
| Zand, H | 1 |
| Pourvali, K | 1 |
| Ghorbani, A | 1 |
| Pani, F | 1 |
| Massidda, M | 1 |
| Pusceddu, V | 1 |
| Puzzoni, M | 1 |
| Massa, E | 1 |
| Madeddu, C | 1 |
| Scartozzi, M | 1 |
| Mariotti, S | 1 |
| Lee, YS | 2 |
| Nana, AW | 3 |
| Wu, HC | 2 |
| Yang, YSH | 2 |
| Wu, SY | 1 |
| Yang, YS | 2 |
| Cheng, TM | 1 |
| Ho, Y | 1 |
| Li, WS | 1 |
| Liao, YM | 2 |
| Liu, YR | 1 |
| Pedersen, J | 1 |
| Incerpi, S | 2 |
| Hercbergs, A | 1 |
| Liu, LF | 2 |
| Wang, LS | 1 |
| Stain, SC | 1 |
| Shih, A | 2 |
| Wu, CH | 1 |
| Zohreh, B | 1 |
| Masoumeh, V | 1 |
| Fakhraddin, N | 1 |
| Omrani, GHR | 1 |
| Fujiwara, Y | 1 |
| Chayahara, N | 1 |
| Mukohara, T | 1 |
| Kiyota, N | 1 |
| Tomioka, H | 1 |
| Funakoshi, Y | 1 |
| Minami, H | 1 |
| Wei, PL | 1 |
| Lu, YT | 1 |
| Pedersen, JZ | 1 |
| Chan, YX | 1 |
| Alfonso, H | 1 |
| Chubb, SA | 1 |
| Fegan, PG | 1 |
| Hankey, GJ | 1 |
| Golledge, J | 1 |
| Flicker, L | 1 |
| Yeap, BB | 1 |
| Rennert, G | 1 |
| Rennert, HS | 1 |
| Pinchev, M | 1 |
| Gruber, SB | 1 |
| Friedman, GD | 1 |
| Schwalbe, JS | 1 |
| Habel, LA | 1 |
| Murai, H | 1 |
| Murakami, S | 1 |
| Ishida, K | 1 |
| Sugawara, M | 1 |
13 other studies available for thyroxine and Colorectal Neoplasms
| Article | Year |
|---|---|
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Proliferation; Colorectal Neoplasms; Drug Resist | 2020 |
Colorectal cancer causes alteration of thyroid hormone profile in newly diagnosed patients.
Topics: Colorectal Neoplasms; Cross-Sectional Studies; Humans; Thyroid Hormones; Thyroxine; Triiodothyronine | 2021 |
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?
Topics: Adenocarcinoma; Aged; Autoimmune Diseases; Cohort Studies; Colorectal Neoplasms; Fatigue; Female; Ho | 2017 |
Thyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer.
Topics: beta Catenin; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Gene Expression R | 2018 |
Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Colorectal Neoplasms; Disease Mo | 2018 |
Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal N | 2018 |
Apigenin-mediated Alterations in Viability and Senescence of SW480 Colorectal Cancer Cells Persist in The Presence of L-thyroxine.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Cell Proliferation; Cell Survival; Cellular Senescence; | 2019 |
Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorecta | 2016 |
Higher thyrotropin concentration is associated with increased incidence of colorectal cancer in older men.
Topics: Age Factors; Aged; Colorectal Neoplasms; Female; Humans; Incidence; Lung Neoplasms; Male; Neoplasms; | 2017 |
A case-control study of levothyroxine and the risk of colorectal cancer.
Topics: Aged; Case-Control Studies; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Female; Humans | 2010 |
Re: a case-control study of levothyroxine and the risk of colorectal cancer.
Topics: Colorectal Neoplasms; Female; Humans; Male; Thyroxine | 2011 |
Elevated serum interleukin-6 and decreased thyroid hormone levels in postoperative patients and effects of IL-6 on thyroid cell function in vitro.
Topics: Aged; Cholecystectomy; Colorectal Neoplasms; Esophageal Neoplasms; Female; Humans; Interleukin-6; Ma | 1996 |